Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M
Prnewswire·2026-03-31 07:00
Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M Accessibility StatementSkip Navigation Throughout the year, we continued to demonstrate resilience and solid profitability, while further strengthening the Company's balance sheet. Looking ahead, we are making strong progress toward the next key milestone: a U.S. public offering, aimed at creating value for our investors." Our pharmaceutical segment is dedicated to developing innovative, non-opioid solutions for chronic pain manag ...